Systematic review of the efficacy of stereotactic ablative radiotherapy for oligoprogressive disease in metastatic cancer

Stereotactic Ablative Radiotherapy (SABR) is now an established treatment option for oligometastatic disease. The results of 9 randomised trials support the suggestion that patients with oligometastatic disease treated with ablative therapies such as surgery, SABR or radiofrequency ablation benefit in terms of progression free survival. The treatment is well tolerated [1 –8]. The landmark phase II SABR-COMET trial has shown a doubling of overall survival at 5 and 8 years [9]. With the increase in available data on the benefit of SABR in oligometastatic disease, clinical practice is now starting to incorporate SABR for oligoprogressive disease.
Source: Radiotherapy and Oncology - Category: Radiology Authors: Tags: Review Article Source Type: research